Study drug GFH009 for relapsed lymphoma after prior treatments
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests GFH009 (given alone) in adults with peripheral T-cell lymphoma that has come back or not responded. It may help shrink lymphoma in people who have already tried several other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- Your lymphoma has been confirmed by a biopsy as peripheral T-cell lymphoma that is relapsed or refractory
- You have had at least 2 and no more than 5 prior treatment “lines,” and they didn’t work
- You have at least one measurable lymphoma spot on scans, and you can provide fresh or stored tumor tissue for testing
- Your overall health is strong enough for treatment (performance status of 0–2) and your organ bloodwork is adequate
- You are well enough to start (at least 12-week life expectancy, and most side effects from prior therapy have improved to mild levels)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (GFH009) combined with another targeted drug (zanubrutinib) for people with diffuse large B-cell lymphoma that has returned or not improved after at least two prior treatments. It aims to see if this combination can shrink tumors and improve outcomes.
This early-stage trial tests a new drug called GSK5926371 in adults whose B-cell lymphoma (a blood cancer) has come back or stopped responding to previous treatments. The study aims to find out if this drug is safe and whether it can help shrink the cancer.
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
This study tests two new drugs (SHR-0302 and SHR-2554) for people with a type of lymphoma (peripheral T-cell lymphoma) that has come back or not responded to prior treatment. The goal is to see if the combination can help control the cancer.
Hear when a new Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.